martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 28, 2026

Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook

View original at finance.yahoo.com
Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Novo Nordisk scores 5 out of 6 on Simply Wall St's valuation checks

    60% confidence
  • Novo Nordisk projected Free Cash Flow reaches DKK 107.4 billion by 2030

    60% confidence
  • Novo Nordisk is undervalued by 65.4% based on DCF analysis, with an intrinsic value of DKK 769.11 per share

    60% confidence
  • Novo Nordisk extrapolated Free Cash Flow reaches approximately DKK 145.9 billion by 2035

    60% confidence
  • Sell-side analysts have provided explicit Free Cash Flow forecasts for Novo Nordisk out to 2030, with Simply Wall St extrapolating further to 2035

    60% confidence
  • Investors have been reassessing Novo Nordisk's growth expectations and risk, shifting sentiment and explaining the mix of short-term gains and long-term declines

    60% confidence
  • Novo Nordisk's 34.5% return over the last year is lagging behind its pharmaceutical peers

    60% confidence
  • 237 more high quality undervalued stocks are identified on Simply Wall St's platform

    60% confidence

Data points we hold from this source

Novo Nordisk · free cash flow52.1 billion_DKK
Novo Nordisk · free cash flow projected107.4 billion_DKK
Novo Nordisk · free cash flow extrapolated145.9 billion_DKK
Novo Nordisk · dcf intrinsic value769.11 DKK_per_share
Novo Nordisk · discount to intrinsic value65.4 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is Novo Nordisk (CPSE:NOVO B) Pricing Reflect Its Recent Share Price Swings And Growth Outlook — Source | Via News | es.VIA.NEWS